Evotec and Yale University have entered into a strategic partnership to jointly assess and potentially pursue novel assays, screens and models, and in particular, exploratory drug targets and compounds in the areas of metabolic diseases, CNS, immunological diseases and cancer. The goal is to integrate Evotec's drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialized.
Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "We are very excited about this open innovation alliance with Yale. There is a tremendous wealth of scientific innovation at Yale that has the potential to be directly translated into first- and best-in-class drug candidates. Together we want to significantly accelerate this process by removing technical bottlenecks and focusing all efforts on bringing individual projects to highest industrial standards in preparation for development and commercialization partnerships with pharma companies."
"This agreement is a new collaboration model between academia and the pharma industry. It essentially gives all faculties at Yale the opportunity to directly translate new biological insights into top-notch drug discovery projects. Evotec is uniquely suited as a partner as they combine an extremely broad drug discovery platform with fast processes and proven commercialization skills," said Dr. Jon Soderstrom, managing director of Yale's Office of Cooperative Research.